Foresight®

png

MYRIAD FORESIGHT® CARRIER SCREEN

YOUR PARTNER IN PLANNING

 

Identify more couples at risk of passing down serious inherited, prevalent, and clinically-actionable conditions.

 

 

WHY MYRIAD FORESIGHT

 

Myriad Women’s Health pioneered expanded carrier screening and our Myriad Foresight Carrier Screen is systemically designed to maximize the detection of at-risk couples for a pregnancy affected by inherited conditions. We offer seamless support and services to make it easy to integrate genetic screening into your practice. This means more of your patients will benefit from valuable information that can make a difference in health outcomes for families.

 

A PANEL WITH A PURPOSE

The goal of carrier screening is to detect couples who are at risk of passing down serious inherited conditions. That’s why we’ve designed the Foresight Carrier Screen to maximize detection rates for the diseases that matter the most.

WE’RE REIMAGINING THE FUTURE OF GENETICS

UNMATCHED AT-RISK COUPLE DETECTION

Have the utmost confidence you aren’t missing couples at risk with the highest published at-risk couple detection rate for serious inherited conditions (1 in 22 couples)1

 

 
SUPERIOR TECHNOLOGY

Unmatched detection rates for the vast majority of genes on our panel (>99% across ethnicities) means you can trust both positive and negative results.

 

PRIORITIZING CLINICAL SIGNIFICANCE IN PANEL DESIGN

Our experts evaluated >650 genes based on strict criteria in an effort to produce not simply more, but meaningful clinical information. Thus, we selected 176 genes for the Foresight Carrier Screen.

 

SEVERITY 

Is this condition mild? Or is it serious (moderate, severe or profound)?

 

ACTIONABILITY 

Is this information helpful to patients?

 

PREVALENCE

Is this condition common enough to be of value?

 

SENSITIVITY

With the best technology available, how well can we identify carriers?

 

FLEXIBLE PANEL CHOICES FOR PERSONALIZED CARE

Universal carrier screening for cystic fibrosis and spinal muscular atrophy is recommended by American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists. (ACOG).4,5 

 

30% more pregnancies affected with cystic fibrosis* can be identified using Myriad Women’s Health’s testing methodology. *when compared to a traditional 23 mutation panel

INCIDENCE OF AFFECTED PREGNANCIES

Approximately 1 in 300 pregnancies are affected by a condition screened by the Myriad Foresight Carrier Screen1

  • Down Syndrome: 1 in 800 births9
  • Open Neural Tube Defects: 1 in 1,000 births10
  • Cystic Fibrosis: 1 in 3,500 births11

 

FORESIGHT TEST DETAILS

CONDITIONS COVERED

176 genes associated with serious and prevalent inherited conditions

WHO TO SCREEN

Men and women planning to start a family

 

WHEN TO SCREEN

 

Before or during pregnancy

 

SAMPLE TYPE

 

4 ml blood, or saliva sample

 

TURNAROUND TIME

 

Results in 2 weeks on average

 

METHODOLOGY

 

Full-exon sequencing with panel-wide deletion calling

 

REFERENCES:

 

  1. Hogan et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry 2018; doi:10.1373/clinchem.2018.286823
  2. Beauchamp KA, Muzzey D, Wong KK, et al. Systematic design and comparison of expanded carrier screening panels. Genetics in Medicine 2017; doi:10.1038/gim.2017.69.
  3. Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner RJ. Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening. 2016; 316(7):734-742.
  4. Prior, Thomas W. 2008. “Carrier Screening for Spinal Muscular Atrophy.” Genetics in Medicine: Official Journal of the American College of Medical Genetics 10 (November). The American College of Medical Genetics: 840
  5. Committee Opinion No. 690 Summary: Carrier Screening in the Age of Genomic Medicine.” Obstetrics and Gynecology 129 (3): 595–96.
  6. Johansen Taber KA et al., Genet Med 2018; https://doi.org/10.1038/s41436-018-0321-0
  7. Global Genes, www.globalgenes.org
  8. Condit, et al. 2003. “Attitudinal Barriers to Delivery of Race-Targeted Pharmacogenomics among Informed Lay Persons.” Genetics in Medicine: (5): 385–92.
  9. de Graaf G, Buckley F, Skotko BG. Estimates of live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet 2015; 167(4):756-767.
  10. Cragan JD, Roberts HE, Edmonds LD, et al. Surveillance for ancephaly and spina bifida and the impact of prenatal diagnosis–United States, 1985-1994. MMWR CDC Surveill Summ 1995 Aug 25; 44(4):1-13.
  11. Cystic Fibrosis Foundation Patient registry 2012 annual data report. Bethesda, Maryland. ©2013 Cystic Fibrosis Foundation

 

For more information please call us or visit www.myriadwomenhealth.com/provider-foresight/

x